Financial Data and Key Metrics Changes - The company reported record revenue of $71.9 million, representing a 24% year-over-year growth and a 14% sequential growth from the second quarter [15] - Gross profit for the quarter was $41.3 million, resulting in a gross margin of 57.5% [15] - Adjusted EBITDA reached $16.1 million, up 16% from the prior year, with a margin of 22.4% [15] - Net income for the quarter was $3.5 million, or $0.09 per diluted share [16] - Trailing 12-month free cash flow totaled $23.3 million, significantly up from the prior year [18] Business Line Data and Key Metrics Changes - Ventilation revenue achieved double-digit year-over-year growth, now accounting for less than half of net revenue for the first time in over a decade [6][7] - New sleep patient starts grew 96% year-over-year, while the resupply population increased 51% year-over-year and 33% sequentially [9] - PAP therapy patients increased 64% year-over-year and 21% sequentially [16] - Maternal health products from the Lehans acquisition are expected to be a significant growth driver in 2026 [10][11] Market Data and Key Metrics Changes - The payer mix is shifting, with lower Medicare exposure as a result of the Lehans acquisition, which is virtually a 0% Medicare company [33] - The company anticipates competitive bidding to return, but remains confident in its ability to win contracts due to operational soundness [28] Company Strategy and Development Direction - The long-term vision is to expand geographic access to high-quality home-based care, diversify product offerings, and deliver operational excellence at scale [5] - The company is focusing on deploying AI-powered revenue cycle management tools to improve efficiency and scalability in billing and collections [11] - The integration of Lehans Medical Equipment is expected to enhance service capabilities and broaden the patient base [4][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to drive future growth and deliver lasting value for patients, partners, and shareholders [12] - The company is updating its full-year outlook, expecting net revenue between $271 million and $273 million and adjusted EBITDA between $60 million and $62 million [20][21] - Management emphasized the importance of disciplined execution and integration of recent acquisitions for profitable growth in 2026 [22] Other Important Information - The company completed its 2025 share repurchase program, repurchasing nearly 2 million shares at an average price of approximately $6.69 [19] - The balance sheet remains strong, with $11.1 million in cash and long-term debt of only $19.6 million [19] Q&A Session Summary Question: Confirmation of organic growth excluding Lehans - Management confirmed organic growth at around 14% [24] Question: Factors driving growth in the sleep segment - Management attributed growth to gaining market share and hiring dedicated sales representatives for sleep products [25][26] Question: Comments on competitive bidding - Management anticipates competitive bidding returning and is prepared to participate [28] Question: Payer mix and authorization friction - Management noted a shift in payer mix and emphasized that Medicare is a reliable payer [33][34] Question: Operational levers to protect margins - Management indicated that while gross margins may face pressure, improvements in SG&A could offset this [36][37] Question: Focus on rural markets for growth - Management stated that the focus remains on expanding in rural markets where they have existing presence [38][39] Question: Declining revenue per patient in sleep therapy - Management clarified that the revenue profile differs between therapy and resupply patients, with stable realizations [42] Question: Priority areas for technological investment - Management highlighted investments in AI for operational efficiencies, particularly in the intake process [43][44]